免疫抑制的炎症性肠病或自身免疫性肝炎儿童接种水痘-带状疱疹病毒疫苗的前瞻性观察研究
本研究前瞻性观察17例3-16岁(炎症性肠病15例、自身免疫性肝炎2例)接受免疫抑制治疗且病情稳定的血清阴性儿童,经接种前清单评估后接种水痘-带状疱疹病毒疫苗共29剂次。所有接种耐受良好,仅2例报告发热和腹痛等轻微副作用,1例接种次日出现克罗恩病复发;接种后VZV-IgG浓度显著升高(p=0.018),所有受试患者体外均可检测到VZV特异性淋巴细胞反应。结论认为在持续免疫抑制的炎症性肠病和自身免疫性肝炎儿童中,VZV疫苗接种耐受良好、安全且具有免疫原性。
要点
- 经接种前清单评估免疫反应性后,持续免疫抑制的炎症性肠病或自身免疫性肝炎儿童可接种VZV疫苗。
- 29剂次接种耐受良好,仅2例出现发热、腹痛等轻微副作用。
- 接种后VZV-IgG浓度显著升高(p=0.018),所有受试患者可检测到特异性淋巴细胞反应。
核心结论
- 在因炎症性肠病和自身免疫性肝炎接受持续免疫抑制的儿童中,VZV疫苗接种耐受良好、安全且具有免疫原性。
- 通过临床和实验室参数确保免疫反应性,而非依据免疫抑制的类型和剂量,是决定免疫抑制儿童是否接种减毒活疫苗的合理方法。
研究设计与样本
- 前瞻性多中心观察性研究,采用接种前清单筛选低强度和高强度免疫抑制患者进行VZV疫苗接种。
- 共17例血清阴性患者(炎症性肠病15例、自身免疫性肝炎2例),年龄3-16岁,完成29剂次VZV疫苗接种。
- 8例接受高强度免疫抑制,6例接受低强度免疫抑制,3例在接种前中断免疫抑制。
- 通过问卷评估免疫后耐受性和安全性,通过VZV-IgG浓度、相对亲和力指数(RAI)和特异性淋巴细胞增殖反应测量免疫应答。
主要发现
- 全部29剂次接种耐受良好,仅2例报告发热和腹痛等轻微副作用。
- 1例患者在接种次日出现克罗恩病复发。
- 接种后VZV-IgG浓度显著升高(p=0.018)。
- 所有受试患者体外均可检测到针对VZV的特异性淋巴细胞反应,且该反应与RAI相关(r=0.489;p=0.078)。
临床怎么用
- 对病情稳定、经接种前清单评估确认免疫反应性的炎症性肠病或自身免疫性肝炎免疫抑制儿童,可考虑接种VZV疫苗。
- 接种决策可依据临床和实验室免疫反应性评估,而非单纯依据免疫抑制的类型和剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Children with inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH) receiving immunosuppressive treatment are at risk for severe varicella zoster virus (VZV)-induced disease. This study evaluated vaccination of susceptible patients with stable disease and documented immunoreactivity without interruption of their current immunosuppression (IS). METHODS: This prospective multicentre observational study used a prevaccination checklist to select patients with low-intensity and high-intensity IS for VZV vaccination. Tolerability and safety after immunization were assessed by questionnaire. The immune response was measured by the VZV-IgG concentration, relative avidity index (RAI), and specific lymphocyte proliferative response. RESULTS: A total of 29 VZV vaccinations were performed in 17 seronegative patients aged 3-16 years (IBD n = 15, AIH n = 2). Eight patients received high-intensity immunosuppression, another six low-intensity immunosuppression, and three patients interrupted IS before VZV vaccination. All 29 vaccinations were well tolerated; only minor side effects such as fever and abdominal pain, were reported in two patients. One patient experienced a flare of Crohn's disease the day after vaccination. The VZV-IgG-concentration increased significantly (p = 0.018) after vaccination, and a specific lymphocyte response towards VZV in vitro was detected in all tested patients which correlated with the RAI (r = 0.489; p = 0.078). CONCLUSIONS: VZV vaccination was well tolerated, safe and immunogenic in children receiving ongoing IS due to IBD and AIH. Ensuring immunoreactivity by clinical and laboratory parameters, rather than the type and dosage of IS, is a reasonable approach to decide on live-attenuated virus vaccinations in immunosuppressed children (German clinical trials DRKS00016357).
引用
- Seitel T, Cagol L, Prelog M, et al. Varicella-zoster-virus vaccination of immunosuppressed children with inflammatory bowel disease or autoimmune hepatitis: A prospective observational study. Vaccine. 2020. PMID: 33160754. doi:10.1016/j.vaccine.2020.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。